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1. Introduction 
Transplant-associated thrombotic microangiopathy (TMA) among early complications after 
hematopoietic stem cell transplantation (HSCT) in children was first described in 1980 (1). 
Incidence varies between centers with an average of 7.9% (0.5-63.6%) (2-4).  
Vascular endothelium is damaged by toxic agents during the preparation regimen for stem 
cell transplantation. Microthrombi develop in small arterioles and capillaries and cause 
partial obstruction. Erithrocytes are subjected to mechanical trauma, and as a result, to 
hemolysis and fragmentation. Patients have clinical symptoms similar to thrombotic 
thrombocytopenic purpura (TTP) and Hemolytic Uremic Syndrome (HUS).  
2. Pathology 
TMA is a pathological definition and characterized by fibrinoid necrosis in vessel walls and 
arteriolar thrombus (5). Following intravascular thrombocyte activation due to microscopic 
damage, thrombus rich in thrombocytes develops in microcirculation. This process depletes 
thrombocytes. On the other hand, blood cells are mechanically damaged due to 
microcirculation obstructed by fibrin particles or microthrombus. The clinical picture is 
microangiopathic hemolytic anemia and thrombocytopenia.  
3. Pathogenesis 
TMA has the characteristics of TTP and HUS. It is seen not only in HSCT but also in all 
patients who had chemotherapy or radiotherapy, in systemic sclerosis, systemic lupus 
erythematosus, antiphospholipid syndrome, malign hypertension, preeclampsia-eclampsia, 
infections, cancers, renal transplantation and with drugs (5-8). 
In primary TTP, there is a deficiency of metalloproteinases which adhere to the very large 
Von Willebrand factor (UL vWF) multimers in vivo and sweep them away from the 
endothelial cells (8-10). This protease is called as “ADAMTS13” and belongs to a disintegrin 
and metalloproteinase with thrombospondin type 1 repeats family (11-15). Severe 
ADAMTS13 deficiency (activity <5%) is seen in 33-100% of patients with primary TTP (16). 
Consequently, newly formed autoantibodies in primary TTP inhibit ADAMTS13 and thus 
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the unswept vWF multimers and thrombocytes aggregate causing a thrombocyte-rich-
thrombus formation in microvascular bed. ADAMTS13 deficiency is found rarely in TMA 
associated with other causes excluding TTP (4).  
While the pathogenesis in transplant-associated TMA is not very clear, it is believed that the 
disease process starts with endothelial damage. In this case, the abnormalities in vascular 
endothelium are independent from ADAMTS13 deficiency. Laurence et al (17), showed that 
apoptosis in microvascular endothelial cells can be induced by plasma from patients with 
primer TTP and HUS in vitro (18). They also demonstrated enhanced apoptosis of 
microvascular endothelial cells in vivo in patient with TTP (19). These studies revealed 
induction of Fas (CD95) in endothelial cells after exposure to TTP plasma, which results in 
apoptosis of human cells (17-19). On the basis of their findings, they proposed that induction 
of endothelial cell injury was an important component of the pathogenesis of TMA. This form 
of injury has been shown to correlate with the generation of platelet microparticles in vitro and 
in patients with classical TTP (20). The mechanism of apoptosis appears to be linked to the 
rapid induction of Fas (CD95) on cultured microvascular endothelium and can be blocked in 
vitro by anti-Fas antibodies, normal cryo-poor plasma and low concentrations of the 
nonspecific protease and endonuclease inhibitor aurintricarboxylic acid. Inhibitors of caspases-
1 and 3 and overexpression of Bcl-XL in cultured microvascular endothelial cells suppress the 
induction of apoptosis in these cells by TTP plasma (21). Apoptosis of microvascular 
endothelial cells may represent a final common pathway of injury leading to the clinical 
expression of microangiopathic hemolytic anemia.  
Endothelial damage causes the secretion of thrombocyte aggregating agent to the 
microvascular circulation. There is an increase in thrombomodulin, P-selectin (GMP-140) 
and tissue plasminogen activator levels (22). Causes of endothelial damage include 
cyclophosphamide, nitrosureas (busulfan), chemotherapeutics, such as platin based agents, 
radiotherapy, cyclosporine and tacrolimus for greft versus host disease (GVHD) 
prophylaxis, cytokines secreted in acute GVHD and infections (fungal, CMV, HHV-6) 
(Figure 1) (23,24).  
The development of the scenario after 3-6 months following chemotherapy/ radiotherapy 
suggests that direct antibodies are formed against the endothelium and thrombocyte 
glycoprotein IV (CD 36) or other intracellular endothelial antigenic targets. IL-1, IL-6, 
soluble IL-2 receptor and TNF plasma levels are increased in primary TTP. The 
histopathologic determinant for TTP/HUS is the presence of intravascular thrombocyte 
aggregating agents with abundant vWF content as seen in disseminated intravascular 
coagulation (DIC) without soluble coagulation factor activation (eg. fibrin deposition). 
There’s abnormal vWF profile in plasma of the patients with primary and transplant-
associated disease. The affinity of vWF multimers to bind thrombocytes is high. 
Specifically, in arteriolar vessels where the flow is high, the aggregated thrombocytes 
form nidus onto which the ULvWF multimers cling. Cryoprecipitate with reduced plasma 
causes less thrombocyte aggregation activity by reducing the ULvWF. Due to this 
reductase activity, blood exchange using cryoprecipitate with reduced plasma is 
performed in severe TTP/HUS (23-25). In addition, thrombomodulin which is related to 
endothelial cell damage, plasminogen activator inhibitor-1 and soluble intercellular 
adhesion molecule increase in patients’ serum (26-31). Increased levels of IL-1, IL-8, TNF 
and IFN expand the inflammation mediated tissue damage via direct toxicity to 
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endothelium. This may lead to acute GVHD or hepatic veno-occlusive disease (VOD) (32-
36). Some investigators even think that the transplant-associated TMA is an endothelial 
form of GVHD (37).  
Cyclosporine when used in GVHD prophylaxis, increases the thromboxane A2 production 
and decreases the prostaglandin I2 production (38, 39). Cyclosporine and most probably 
tacrolimus show direct toxicity to endothelium (40-45) and addition of sirolimus to 
calcinorin inhibitors potentializes these toxic effects (46-48).     
 
Endothelial cell injury and apoptosis have been associated with generation of endothelial microparticles 
that may be relaased in to the circulation. Release of endothelial microparticles has been associated with 
procoagulant activity. Furthermore, endothelial microparticles induce platelet aggregation, and thus by 
inducing microthrombosis could predispose to TMA.  
Abreviations: CSA; cyclosporin-A, GVHD; Graft-versus-host disease, TBI; Total body irradiation, TMA;  
thrombotic microangiopathy 
Fig. 1. Pathogenesis of Transplantation associated thrombotic microangiopathy. 
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4. Risk factors for TMA 
1. Female gender 
2. Age: less frequent in children compared to adults.  
3. Donor type: more frequent in unrelated donors and mismatch related donors. 
4. Severity of the primary disease.  
5. Nonmyeloablative transplant (Fludarabine based conditioning regimens) 
6. High dose busulfan use (16 mg/kg) 
7. Use of antithymocyte globulin or total body irradiation 
8. Presence of 2nd or more degree acute GVHD 
9. Cyclosporine, tacrolimus, sirolimus use 
10. Neuroblastoma patients specifically with a history of cisplatin treatment 
11. Presence of an infection, especially CMV. We reported that in a patient who developed 
TMA together with CMV infection, TMA signs resolved completely after successful 
treatment of CMV infection (49). 
12. Stem cell source; Elliott et al. (12) reported that 4 of the 25  (16 %) bone morrow 
transplantations from a HLA full matched sibling resulted in TMA, however, none of the 
45 peripheral stem cell transplantations from a HLA full matched sibling resulted in TMA. 
They defined the use of bone marrow as a stem cell source as a risk factor. They also stated 
that prospective, large and comparative studies were needed in order to understand the 
relationship between TMA and the stem cell source. As opposed to their results, 3 of the 18 
patients (16.6. %) in our study who used peripheral blood for the source of stem cells 
developed TMA while none of the 32 patients who used the bone morrow developed it. 
We concluded that the use of the peripheral stem cell was a risk factor for TMA (50). Like 
Elliott et al., we also think that prospective, large and comparative studies are needed in 
order to understand the relationship between TMA and the stem cell source. 
5. Clinical signs 
Signs develop in an average of 44-171 days after the transplantation. In 2/3 of the cases, the 
disease occurs before 100 days (51). Erythrocytes are fragmented by microangiopathic 
damage and erythrocyte turnover increases without immune mediated hemolysis or DIC. 
Peripheral smear shows fragmented erythrocytes (schistocytes). Mild hemolysis, severe 
anemia, thrombocytopenia, fever, hematuria, mental disability, and kidney failure requiring 
dialysis may be present in patients. Biochemically, serum lactate dehydrogenase (LDH) is 
increased, haptoglobulin level is decreased. In addition, indirect hyperbilirubinemia and 
hemoglobinuria may be seen.   
Fragmented erythrocyte ratio is 4-10% in transplant-associated TMA. Nucleated 
erythrocytes may be found in peripheral circulation. Thrombocyte consumption is increased 
although DIC is not present. Plasma vWF level is high albeit not pathognomonic. Studies 
demonstrate that vWF level increases more in allogeneic stem cell recipients compared to 
autologus recipients. The highest levels of vWF are seen in 3-4 months after the 
transplantation when TMA is also clinically presented.  
6. Diagnostic criteria for transplant-associated TMA 
In a study by George et al (2), a total of 28 parameters were detected to be used for diagnosis 
in various centers. It is also observed that such a wide range of diagnostic criteria use caused 
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variability in incidence ranging from 0.5-63.6%. As a result, an international research group 
was organized and a consensus on diagnostic criteria was reached. According to this 
consensus, the following diagnostic criteria were determined (3). 
1. Presence of schistocytes 
2. Presence of prolonged or progressive thrombocytopenia (<50x109/l)  or 50% or more 
decrease in the previous thrombocyte count) 
3.  Sudden and persistent LDH increase 
4. Decrease in hemoglobin concentration or increase in transfusion needs 
5. Decrease in serum haptoglobulin level 
Each criteria needs to be fulfilled for diagnosis. Sensitivity and specificity are 80% (3).  
7. Differential diagnosis 
7.1 Cyclosporine toxicity   
Isolated microangiopathy: 1-2% erythrocyte fragmentation is seen in most patients treated 
with cyclosporine or tacrolimus after transplantation. At toxic serum levels of these drugs, 
fragmented erythrocytes increase to 3-4%, indirect bilirubin is increased and reticulocytosis 
is observed.When cyclosporine dose is decreased and the serum drug levels turn to 
therapeutic levels, hemolysis and renal effects return to normal. Vitamin E may treat 
hemolysis after transplantation. 
Cyclosporine associated central nervous system dysfunction: This picture is frequently 
mistaken as TMA in the first 6 months after transplantation. Seizures, alterations in 
conciousness, apraxia/ataxia or cortical blindness may be seen in patients. These symptoms 
are usually related with uncontrolled hypertension, renal tubular acidosis and magnesium 
loss. Symptoms resolve within 48-72 hours with the reduction of cyclosporine dose. In 
treatment, cyclosporine should be stopped temporarily, another drug should be used for 
GVHD prophylaxis, hypertension should be controlled, magnesium should be replaced and 
if necessary an antiepileptic drugs should be used. If cyclosporine is restarted in patients 
with cortical blindness, speech disturbance or coma, symptoms may reappear. In some 
patients cyclosporine maybe replaced by tacrolimus uneventfully. Behavioural disturbances, 
alterations in conciousness level and seizures are observed both in cyclosporine toxicity and 
TMA. Cortical blindness and apraxia/ataxia are more frequently associated with 
cyclosporine toxicity and are reversible (23). 
7.2 Immune hemolytic anemia 
Immune hemolytic anemia may develop after transplantation, especially in patients who 
had received multiple transfussions prior to HSCT (eg patients with hemoglobinopathies). 
There is increased need for erythrocyte supplementation in these patients. Fragmented 
erythrocytes are detected in peripheral smear, reticulocyte count, LDH and indirect bilirubin 
levels are increased, haptoglobulin is decreased. While direct antiglobulin (direct coombs) 
test is positive in these patients, it is negative in transplant-associated TMA. 
7.3 Disseminated intravascular coagulation 
Hemostatic system is a dynamic system that under normal conditions is balanced by 
thrombus formation via the conversion of prothrombin to thrombin and thrombus 
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degradation via elimination of trombin with antithrombin before it promotes coagulation. 
Disturbance of this balance by any reason leads to aggregation of fibrin and thrombin and 
thus, to this clinical condition secondary to the activation of fibrinolysis which may result 
in death. Fibrin is widely accumulated (microthrombus) in small vessels of various organs 
due to thrombin effect. Fibrin accumulation leads to consumption of mainly thrombocytes 
and fibrinogen, several coagulation factors (II, V, VIII) and erythrocytes. Accumulated 
fibrin in vessels is lysed when the fibrinolytic system is activated and fibrin degradation 
products (FDP) pass to the circulation (secondary fibrinolysis). Fibrin aggregates in small 
vessels may cause ischemic tissue necrosis (bilateral renal necrosis, surrenal necrosis) and 
in some instances where fibrin ligaments have accumulated to completely obstruct the 
vessel lumen, microangiopathic hemolytic anemia may develop. 
Clinical presentation may vary from being asymptomatic to shock. Bleeding occurs as a 
result of coagulation factors and platelet depletion. It maybe observed as petechiae and 
echymosis, oozing from injection sites and gums, subcutaneous hematomas, nasal bleeding, 
hematuria, gastrointestinal and intracranial hemorrhage. 
Ischemic organ damage due to intravascular thrombosis may be seen. Furthermore, in 
chronic DIC, due to fibrin deposition in glomerules, renal insufficiency characterized by 
oliguria frequently accompanies the case.  
Thrombi and fibrin materials formed as a result of the damage that erythrocytes have 
incurred during their flow through the vessels, block the vessel lumen. This condition 
causes microangiopathic hemolytic anemia.  
In the diagnosis of DIC; fibrinogen level is low, prothrombin time is prolonged, actiavted 
partial thromboplastin time is prolonged, factor II, V, VIII and XIII levels are low and 
thrombocytopenia is present. Final diagnosis is made by the demonstration of fibrinogen-
fibrin degradation products in serum using immunoassay. FDP has high levels and fibrin 
monomer polymerization is prolonged. The D-dimer test is specific for fibrin proteolysis. 
Fibrin complexes are high in circulation. If the fibrinogen is lower than 1 g/L, thrombin time 
is prolonged, however if fibrinogen level is higher than 1 g/L and thrombin time is 
prolonged, this means the FDP is increased. 
When microangiopathic hemolytic anemia develops, fragmented erythrocytes are found in 
peripheral blood smear. Reticulocyte count is increased secondary to hemolysis. 
Thrombocytopenia and absence of thrombocyte aggregates in peripheral smear may be seen 
as a result of platelet consumption in microvascular thrombosis and platelet activation of 
circulating thrombin. Antithrombin III is decreased, euglobulin lysis time is shortened. 
Search for fibrin monomer formation and fibrinopeptide measurements are more 
complicated tests however used rarely for confirmation of diagnosis.  
8. Treatment 
Currently there is no any consensus on the therapy of TMA. However, there is no any 
randomized trials regarding to treatment. Once transplant-associated TMA is suspected, the 
potentially blamed drugs such as cyclosporine, tacrolimus or sirolimus should be seized. 
Necessary immunosupression should be provided by corticosteroid, mycophenolate and 
azathiopurine. In a patient using cyclosporine, the drug may be replaced by tacrolimus but 
this usually does not help (52).  
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8.1 Plasma exchange 
Despite limited data, many centers use plasma exchange as part of the treatment in 
transplant-associated TMA. Plasma exchange using cryoprecipitate with reduced plasma or 
fresh frozen plasma may be used alone or in combination with staphylococcal protein 
immunoabsorption. Its efficiency is controversial. Response rate to plasma exchange, when 
compared with primary TTP (75%), is significantly less in transplant-associated TMA 
(<50%) (32, 53). Furthermore, the mortality in transplant-associated TMA is greater than 
80% when plasma exchange used whereas it is 20% in idiopathic TTP (16, 32, 53-55). Limited 
response to plasma exchange and high mortality rate despite plasma exchange are 
associated with ADAMTS13 levels. In primary TTP, ADAMTS13 activity is inhibited by 
autoantibodies is restored by plasma exchange, thus the underlying disease mechanism is 
reversed and clinical outcome is positive. However, in transplant-associated TMA, since the 
case is independent from ADAMTS13 activity the response rates are low in spite of plasma 
exchange. On the other hand, 28% of patients treated with plasma exchange had 
complications such as infections due to plasmapheresis catheter or transfused plasma, 
thrombosis, hemorrhage, pneumothorax, pericardial tamponade, hypoxia, hypotension, 
serum sickness, and anaphylaxis (56-58).  
Based on the absence of convincing data in published series and high complication rates, 
some researchers emphasize not to use plasma exchange routinely for transplant-associated 
TMA until new clinical study results are available or at least to rule out other factors that 
could cause TMA (eg.infections, GVHD) before use (54, 59).  
8.2 Defibrotide 
Recently, the most pronounced agent is defibrotide, a polideoxyribonucleotide salt. 
Defibrotide has antithrombotic and thrombolytic activity and inhibits the TNF mediated 
endothelial cell apoptosis in-vitro (60). Defibrotide’s main effect is local on vascular bed. It 
does not have a significant effect on systemic coagulation. Defibrotide has protective effects 
on damaged or activated endothelial cells especially in small vessels. Defibrotide once 
bound to vascular endothelial cells decreases their procoagulant activity and increases their 
fibrinolytic potentials. The drug also has anti-inflammatory and anti-ischemic effects (35, 
61). The effectivity of defibrotide has been shown in hepatic VOD treatment (35-36). In a 
study by Corti et al, 12 TMA patients were reported to be treated with defibrotide, 6 patients 
had complete remission, 3 had partial remission (61). In coclusion, considering the similarity 
between VOD and transplant-associated TMA and that the endothelial damage is held 
mainly responsible for pathogenesis, large scale randomized studies with defibrotide are 
required.  
8.3 Other therapeutic approaches 
Literature reveals a few other treatment approaches with different outcomes (Table 1). Wollf 
et al, described complete remission in 9 out of 13 patients with TMA and GVHD whose 
treatments for GVHD by calcinorin inhibitors were stopped and replaced with anti-CD25 
antibody (daclizumab). Five of those patients with complete remission for TMA also had 
complete remission for GVHD. While 4 patients were still alive 266 days after the 
transplantation, 1 died due to relapse of the primary disease and the rest 8 died due to 
infections, GVHD or multiorgan dysfunction (62).  
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Au et al, treated 5 patients refractory to plasma exchange and high dose corticosteroid 
therapy with a total of 4 doses of rituximab once a week. Four patients had complete 
remission, one of which later died due to sepsis. The patient without remission died 3 weeks 
later due to multiorgan failure (63). The mechanism of action for rituximab in transplant-
associated TMA is not clear, nevertheless, is thought to be related with the 
immunomodulator effectivity of the drug. 
Takatsuka et al, used eicasopentaneoic acid (EPA) to decrease the inflammation related 
complication such as TMA in peritransplantation period. Sixteen patients were enrolled in 
this study. EPA was started 3 weeks prior to the transplantation in 7 patients who have 
undergone allogeneic transplantation from unrelated donors and continued up to 180 days 
after the procedure. EPA was not given to the other 9 patients. All patients had similar 
preparation regimes and GVHD prophylaxis. Four patients developed TMA and 5 patients 
died in the group not receiving EPA. In the group receiving EPA, non developed TMA and 
all survived until 143 days after the transplantation (64).  
Kajiume et al used transdermal isosorbide successfully in a case and have not reported any 
side effects (65).  
8.4 Future approaches 
TNF inhibitors such as etanercept and infliximab are demonstrated to be effective in 
acute GVHD treatment. Theoretically they are thought to be effective in transplant-
associated TMA as well (66-71). However, TNF inhibitors’ potentially increasing  
the risk of opportunistic infections such as fungal and viral infections limits their use (67-
70).  
Statins decrease the endothelial inflammatory response and myocardial ischemia (72-75). 
Iloprost is a prostacycline analogue decreasing the endothelial cell damage and the markers 
increasing during its activation (76). Endothelin receptor antagonists reverse the 
microvascular damage induced by cyclosporine in vitro (77), shows protective effect against 
endothelial damage due to ischemia/reperfusion in vivo (78). Edaravone is a free radical 
scavenger inhibiting the vascular endothelial cell damage in patients with myocardial 
ischemia and cerebrovascular trauma. In animal models, it decreases the thrombogenesis 
associated with damaged endothelium via increasing the nitric oxide synthesis (79). Also in 
animal models, edaravone was found to decrease cysplatin induced renal toxicity (80). 
Currently edaravone is approved for ischemic stroke treatment only. Table 2 shows agents 
that have not been used for transplant-associated TMA but have a certain potential to be 
used.  
9. Prognosis 
Being a feared complication of HSCT, transplant-associated TMA has bad prognosis. 
Literature search yields a mortality rate of more than 60% (2). High mortality rate is 
multifactorial; related not only with TMA associated kidney failure, myocardial dysfunction 
and brain ischemia but also with other confounding severe complications of transplantation 
(eg. infections, GVHD). In several series, prognostic factors were evaluated and bad 
prognostic criteria were listed below (37, 46, 81, 82).  
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1. Age equal to or greater than 18. 
2. Unrelated or haploidentic donor 
3. Increased TMA index (LDH/platelet ratio) 
4. Schistocyte count > 5-10 hpf 
5. Patients not exposed to sirolimus 
6. Presence of nephropathy 
Additionally, some authors think that delays in diagnosis and/or treatment are also 
associated with high mortality. 
In conclusion, TMA is a severe complication yet to be investigated thoroughly since the 
pathogenesis is not clear, there is no consensus on treatment and morbidity-mortality rates 
are high.  
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